|
September 2, 2010
|
| 09:07 EDT |  | SNY |
| theflyonthewall.com: | Piper Jaffray's Specialty Pharma/Biotech research teams hold a conference call | | Specialty Pharmaceuticals/Biotech Analyst Research Teams, along with Dr. Kachuck, Director of the USC Multiple Sclerosis Comprehensive Care Center, discuss the role of new oral agents for MS including Novartis' Gilenia, Marck KGaA's Cladribine and agents such as Teva's Laquinimod and Genzyme's Campath. Also to be discussed are the impact new agents may have on current standard-of-care treatments including Copaxone, Avonex and Tysabri on an Analyst/Industry conference call to be held on September 8 at 1 pm hosted by Piper Jaffray. :theflyonthewall.com |
|
|
September 1, 2010
|
| 13:46 EDT |  | SNY |
| theflyonthewall.com: | Sanofi-Aventis says control of atrial fibrillation not achieved in study | | Sanofi-aventis announced that results from the RealiseAF registry show that control of atrial fibrillation was not achieved in more than 40% of the AF patients included in this 10,000 patient cross-sectional registry, as presented today during the European Society of Cardiology Congress in Stockholm, Sweden. In addition, the registry revealed that a majority of patients complain of symptoms, even when AF is controlled. :theflyonthewall.com |
|
| 06:19 EDT |  | SNY |
|
|
August 31, 2010
|
| 14:35 EDT | | SNY |
| theflyonthewall.com: | Genzyme CEO: the company may be sold, but not for $69/share, the Globe reports |
 Subscribe for More Information :theflyonthewall.com |
|
| 12:20 EDT |  | SNY |
|
| 07:51 EDT |  | SNY |
|
|
August 30, 2010
|
| 14:26 EDT | | SNY |
| theflyonthewall.com: | Genzyme sale price will ultimately be in $75-$77.50 range, says MKM Partners | | MKM believes the ultimate takeover price for Genzyme (GENZ) will be in the $75.00-$77.50 per share range and expects Sanofi-Aventis (SNY) has the ability to raise its bid to enter merger discussions. :theflyonthewall.com |
|
| 12:25 EDT | | SNY |
| theflyonthewall.com: | Market averages weaken further | | Muted data on the income and inflation fronts this morning failed to stir the markets much and did little to calm fears about the weak economy. However, some individual stocks bucked the market trend and rallied in the wake of corporate developments. Genzyme (GENZ) rose after the company received and rejected a $18.5B takeover bid from Sanofi-Aventis (SNY). Cogent (COGT) also climbed on news that it will be purchased by Dow component 3M (MMM). Hewlett-Packard (HPQ) shares got a boost after the technology titan announced a $10B share-repurchase plan amid its pursuit of a deal to acquire 3Par (PAR). On Friday, the government will release its monthly jobs report, the importance of which has increased in significance as Wall Street tries to get a handle on the economy. The Dow is down 61 points to 10,089. :theflyonthewall.com |
|
| 12:14 EDT | | SNY |
| theflyonthewall.com: | On The Fly: European Markets Wrap-up | | European stocks were lower today even after the European Commission reported an index of executive and consumer sentiment in the 16 euro nations rose to 101.8, beating estimates...UNITED KINGDOM: The London Stock Exchange is closed today...GERMANY: The DAX was down 0.65% to 5912. Volkswagen (VLKAY) and Bayerische Motoren Were down after Renault-Nissan said U.S. car sales were below expectatiions...FRANCE: France's CAC was down 0.58% to 3,482.Sanofi-Aventis SA (SNY) was up 1.4% after the French Pharmaceutical company initiated the possibility to a hostile bid for Genzyme (GENZ)...Renault was down 1.4% to EUR32.08 euros, after its CEO said that car sales in the U.S. are “a bit weaker” than forecast and recovery worldwide “a bit bumpy". :theflyonthewall.com |
|
| 10:12 EDT |  | SNY |
| theflyonthewall.com: | Genzyme overall volatility collapses; rejects proposal from Sanofi-Aventis | | Genzyme (GENZ) is recently up $2.41 to $70.01. GENZ rejected Sanofi-Aventis (SNY) proposal to acquire all the outstanding shares of GENZ for $69 per share in cash. Call option volume of 16K contracts compares to put volume of 6K contracts. September put option implied volatility is at 23, below a level of 38 from August 26; October is at 27, below a level of 40 from August 17. GENZ average option implied volatility over the last 26-weeks is 33, suggesting decreasing price movement according to Track Data, suggesting decreasing price movement. :theflyonthewall.com |
|
| 09:00 EDT | | SNY |
|
| 08:40 EDT | | SNY |
| theflyonthewall.com: | Sanofi-Aventis says "all alternatives" will be considered to acquire Genzyme | | Sanofi-Aventis CEO Chris Viehbacher said "all alternatives" will be considered to acquire Genzyme after Genzyme rejected the company's $18.5B offer and said it is not ready to engage in talks, according to Bloomberg. :theflyonthewall.com |
|
| 08:12 EDT | | SNY |
|
| 07:47 EDT | | SNY |
|
| 07:38 EDT | | SNY |
|
| 07:15 EDT | | SNY |
| theflyonthewall.com: | Sanofi-Aventis bid for Genzyme equals around $74 per share, says Piper Jaffray |
Subscribe for More Information :theflyonthewall.com |
|
| 07:02 EDT | | SNY |
|
| 06:15 EDT | | SNY |
| theflyonthewall.com: | Sanofi-Aventis could go hostile with Genzyme bid, Telegraph reports | | Sanofi-Aventis (SNY) is reportedly prepared to go hostile with its $18.5B bid for Genzyme (GENZ), the Telegraph reports. After weeks of rumored interest in the company, Sanofi says it is "prepared to consider all alternatives to successfully complete the transaction." Yesterday, Sanofi CEO Christopher Viebacher reportedly sent a "bear hug" letter to Genzyme CEO Henri Termeer, in which he said Genzyme's management was unwilling to meet with the French company, and said Sanofi had been "left with no choice but to take our compelling proposal directly to your shareholders by making its terms public." Reference Link :theflyonthewall.com |
|
| 06:14 EDT |  | SNY |
|
| 05:17 EDT | | SNY |
|
|
August 29, 2010
|
| 20:41 EDT | | SNY |
|
| 14:19 EDT | | SNY |
| theflyonthewall.com: | Sanofi-Aventis offers $69 per share in cash for Genzyme | | Sanofi-aventis (SNY) announced that it has submitted a non-binding proposal to acquire Genzyme (GENZ) in an all-cash transaction valued at approximately $18.5B. Under the terms of the proposed acquisition, Genzyme shareholders would receive $69 per Genzyme share in cash, representing a 38% premium over Genzyme's unaffected share price of $49.86 on July 1, 2010. Sanofi-aventis' offer also represents a premium of almost 31% over the one-month historical average share price through July 22, 2010, the day prior to press speculation that sanofi-aventis had made an approach to acquire Genzyme. Based on analyst consensus estimates, the offer represents a multiple of 36 times Genzyme's 2010 earnings per share and 20 times 2011 earnings per share. Accordingly, the offer price takes into account the upside potential of the anticipated recovery in Genzyme's performance in 2011. Sanofi-aventis has secured financing for its offer. The non-binding offer, which was made on July 29, 2010, was reiterated in a letter sent today to Genzyme's Chairman, President and Chief Executive Officer, Henri A. Termeer, after several unsuccessful attempts to engage Genzyme's management in discussions. Sanofi-aventis is disclosing the contents of its letter in order to inform Genzyme's shareholders of the significant shareholder value and compelling strategic fit inherent in a combination of the two companies. :theflyonthewall.com |
|
| 12:56 EDT | | SNY |
| theflyonthewall.com: | AstraZeneca's Brilinta needs no genetic testing | | A new genetic substudy of PLATO (A Study of PLATelet Inhibition and Patient Outcomes) showed that the effects on a combined primary endpoint of cardiovascular death, myocardial infarction, or stroke seen in Acute Coronary Syndromes, ACS, patients who received the investigational oral antiplatelet treatment, ticagrelor-BRILINTA (AZN), were maintained, whether or not they had the genetic variability that has been previously shown to affect a patient's response to clopidogrel. The substudy is the first to look at both efficacy and bleeding endpoints of ACS patients treated with ticagrelor who carry variations in the CYP2C19 and ABCB1 genes. The data were presented today at the European Society of Cardiology-ESC- congress in Stockholm, Sweden and simultaneously published in The Lancet. :theflyonthewall.com |
|
|
August 27, 2010
|
| 08:33 EDT | | SNY |
|
|
August 26, 2010
|
| 10:42 EDT | | SNY |
| theflyonthewall.com: | Leerink's biotech analyst holds an analyst/industry conference call | | Biotech Analyst Fernandez discusses expectations that BMY/PFE's Apixaban will have a strong position in the $10-$20B warfarin replacement market and discusses the potential risks and opportunities for primary competitors JNJ/BAYRY's Xarelto and Boehringer Ingelheim's Pradaxa on an Analyst/Industry conference call being held on August 27 at 11 am hosted by Leerink. :theflyonthewall.com |
|
| 10:24 EDT | | SNY |
| theflyonthewall.com: | Continue to view Momenta Pharma as a takeover candidate, says Rodman & Renshaw | | Rodman & Renshaw reiterates its view that Momenta Pharmaceuticals (MNTA) should be on major generic and big pharma companies "to-acquire" watch list following the July 23rd approval of the m-Enox ANDA, which validated Momenta's technology. The firm views Novartis (NVS) as the most logical acquirer among big pharma and Teva (TEVA) at the top of the list among generics. :theflyonthewall.com |
|
| 08:12 EDT | | SNY |
|
| 07:20 EDT | | SNY |
| theflyonthewall.com: | L'Oreal says not planning to sell Sanofi stake in short term, Reuters reports | | L'Oreal (LRLCY) CEO Jean-Paul Agon says the company is a "happy investor" in Sanofi-Aventis (SNY) and is not planning to sell its 9% stake, which is worth about $6.7B, in the near-term. Agon says the company "would be happier if the (share) price was higher" and notes that the stake is a financial investment and not a strategic one. Reference Link :theflyonthewall.com |
|
| 06:17 EDT | | SNY |
|
| 05:28 EDT | | SNY |
| theflyonthewall.com: | L'Oréal, Total said to be wary on Sanofi bid for Genzyme, Reuters reports | | L'Oreal (LRLCY) and Total (TOT), Sanofi-Aventis' (SNY) top two shareholders, are reportedly wary about plans by the drugmaker to buy Genzyme (GENZ), Reuters reports. Bankers say the investors "will have a view on not spending too much money." The cosmetics group is reportedly not opposed to a deal in principle, "but was not sure Genzyme was the best buy." Reference Link :theflyonthewall.com |
|
| 05:07 EDT | | SNY |
|
|
August 25, 2010
|
| 12:02 EDT | | SNY |
| theflyonthewall.com: | On The Fly: U.S. Mid-Day Market Wrap-Up | | U.S. stocks were mostly lower following disappointing economic data on home sales and durable goods orders, fueling more uncertainty over the economic recovery... At mid-day, the DJIA was down 0.13% to 10,027.21, the Nasdaq was up 0.05% to 2,124.74 and the S&P 500 was down 0.26% to 1,049.14...MARKET NEWS: Bloomberg reported that Sanofi-Aventis (SNY), down 0.28%, is not willing to pay above $70 per share for Genzyme (GENZ), down 0.18%, and may consider alternative takeover targets. Three sources say Sanofi may consider pursuing companies like Allergan (AGN) or Celgene (CELG) if its Genzyme attempt fails. Dealreporter says Sanofi could raise its bid to $75 per share... Apple (AAPL) is reportedly close to an agreement with Disney (DIS) to offer rentals for some ABC television shows through iTunes, the Wall Street Journal reported. The company is also said to be in talks with News Corp (NWS) to let iTunes users rent TV shows for 99c... Corinthian Colleges (COCO) rose 5.05% on renewed speculation that Apollo Group (APOL) may install their education programs within Corinthian's. :theflyonthewall.com |
|
| 10:49 EDT | | SNY |
| theflyonthewall.com: | Sanofi-Aventis may raise bid for Genzyme, Dealreporter reports | | According to Dealreporter sources, Sanofi-Aventis may raise its bid to $75/share for Genzyme (GENZ). :theflyonthewall.com |
|
| 09:25 EDT | | SNY |
|
|
August 24, 2010
|
| 05:11 EDT | | SNY |
|
